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High-throughput, sensitive, and cost-effective HIV drug resistance (HIVDR) detection assays are needed for large-scale monitoring of
the emergence and transmission of HIVDR in resource-limited settings. Using suspension array technology, we have developed a mul-
tiplex allele-specific (MAS) assay that can simultaneously detect major HIVDR mutations at 20 loci. Forty-five allele-specific primers
tagged with unique 24-base oligonucleotides at the 5= end were designed to detect wild-type and mutant alleles at the 20 loci of HIV-1
subtype C. The MAS assay was first established and optimized with three plasmid templates (C-wt, C-mut1, and C-mut2) and then
evaluated using 148 plasma specimens from HIV-1 subtype C-infected individuals. All the wild-type and mutant alleles were unequivo-
cally distinguished with plasmid templates, and the limits of detection were 1.56% for K219Q and K219E, 3.13% for L76V, 6.25% for
K65R, K70R, L74V, L100I, K103N, K103R, Q151M, Y181C, and I47V, and 12.5% for M41L, K101P, K101E, V106A, V106M, Y115F,
M184V, Y188L, G190A, V32I, I47A, I84V, and L90M. Analyses of 148 plasma specimens revealed that the MAS assay gave 100% concor-
dance with conventional sequencing at eight loci and >95% (range, 95.21% to 99.32%) concordance at the remaining 12 loci. The dif-
ferences observed were caused mainly by 24 additional low-abundance alleles detected by the MAS assay. Ultradeep sequencing analy-
sis confirmed 15 of the 16 low-abundance alleles. This multiplex, sensitive, and straightforward result-reporting assay represents a new
efficient genotyping tool for HIVDR surveillance and monitoring.
It is estimated that 8.2 million people were receiving antiretro-viral therapy (ART) in low- and middle-income countries at the
end of 2011, a dramatic 26-fold increase from 2003 (1). As access
to ART continues to expand worldwide and without adequate
virological monitoring of patients on ART, the emergence and
transmission of HIV drug resistance (HIVDR) are valid concerns.
In resource-limited settings, studies have revealed that transmit-
ted drug resistance (DR) in recently HIV-infected populations is
rising in some countries where access to ART had previously been
expanded (2–6), while acquired DR had been detected in a major-
ity of the patients failing to respond to ART (3, 7, 8).
To preserve the efficacy of the limited first-line antiretroviral
(ARV) drugs and to prevent the emergence and transmission of
HIVDR, it is imperative to conduct HIVDR surveillance and
monitoring in resource-limited settings. Data from DR surveil-
lance and monitoring will allow for making evidence-based deci-
sions on the need for ART guideline changes and assisting in the
promotion of best practices in the provision of ART services that
lead to higher rates of viral suppression and prevention of both
acquired and transmitted HIVDR (9, 10).
In the past few decades, two types of genotypic DR detection
assays, sequencing-based and allele-specific assays, have been de-
veloped for detecting HIVDR mutations. Conventional sequenc-
ing-based assays, such as the FDA-approved and commercially
available genotyping assays, ViroSeq (11) and TruGene (12), and
many in-house assays (13–15), have been widely used for HIVDR
detection analyses in clinical settings and surveillance purposes.
These assays can provide detailed sequence information and de-
tect all possible mutations that are present in an amount above
the detection limit, but they are generally labor-intensive and
not sensitive enough to detect low-abundance mutations. Ul-
tradeep sequencing and single-genome sequencing have also
been utilized in HIVDR detection analyses in recent years and
are highly sensitive in detecting low-abundance mutations;
however, these assays require highly technical skills and are
expensive, and they have not been used in routine surveillance
in resource-limited settings (16–18).
The other type of genotypic assay is allele-specific assays. Sev-
eral allele-specific assays have been developed, including oligonu-
cleotide ligation assay (OLA), parallel allele-specific sequencing
(PASS) (19, 20), allele-specific PCR (AS-PCR) (21–29) and
LigAmp (21, 30). These assays offer substantial improvements in
their detection sensitivity over conventional sequencing-based as-
says and are less expensive, and the results are easy to interpret.
However, a major limitation of existing allele-specific assays is that
they can only detect one or a few mutations at a time. This has
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limited their use in routine HIVDR surveillance and monitoring.
Here, we report the development of a multiplex allele-specific
(MAS) DR detection assay based on suspension array technology
(31, 32) for high-throughput and sensitive detection of HIVDR
mutations, which may be a feasible genotyping tool for large-scale
HIVDR surveillance and monitoring in resource-limited settings.
(Data from this study were presented in part at the Interna-
tional Workshop on HIV and Hepatitis Virus Drug Resistance and
Curative, 5 to 9 June 2012, Sitges, Spain.)
MATERIALS AND METHODS
Design of allele-specific primer extension primers. Based on the current
WHO recommendations for first- and second-line ARVs in resource-limited
settings, we designed allele-specific primer extension (ASPE) primers target-
ing the drug resistance mutations (DRMs) at 20 loci of HIV-1 subtype C that
are associated with resistance to commonly used ARVs in resource-limited
settings. These include eight mutations associated with resistance to nucleo-
side reverse transcriptase inhibitors (NRTIs) (M41L, K65R, K70R, L74V,
Y115F, Q151M, M184V, and K219Q/E), seven mutations associated with
resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs)
(L100I, K101P/E, K103N/R, V106A/M, Y181C, Y188L, and G190A), and five
mutations associated with resistance to protease inhibitors (PIs) (V32I,
I47A/V, L76V, I84V, and L90M). For each of the 20 mutation loci, one ASPE
primer was designed for the wild-type (WT) and one or two primers were
designed for the mutant (Mut) allele(s) based on the HIV-1 subtype C
consensus sequence obtained from the HIV sequence database (see http:
//www.hiv.lanl.gov/content/sequence/NEWALIGN/align.html). Since
five loci have two types of Mut alleles, 20 WT alleles and 25 Mut alleles
were included in the assay (i.e., a total of 45 ASPE primers were designed).
The specificity of each primer was confirmed by NCBI BLAST program
analyses (http://www.ncbi.nlm.nih.gov/BLAST/). The ASPE primers
contained an allele-specific nucleotide at the 3= end for each of the WT
and Mut alleles, and at the 5= end, they contained a unique 24-base Tag
(Luminex Corp., Austin, TX) that is complementary to the anti-Tag on
each of the MagPlex-TAG microspheres (Luminex Corp.) for distin-
guishing each of the alleles by the suspension array system. We incor-
porated degenerate bases into the primers to accommodate polymor-
phisms adjacent to the targeted alleles. The lengths of primers were
between 24 and 39 nucleotide bases with melting temperatures (Tm) of
around 60°C. Table 1 shows the 45 ASPE primer sequences.
Construction of HIV-1 subtype C wild-type and mutant plasmids.
In the initial assay development, three 990-bp DNA fragments represent-
ing WT and Mut types based on the subtype C reference sequence (Gen-
Bank accession no. AF457054) (33) were designed. The DNA fragments
were synthesized and individually cloned into pUCminusMCS plasmids
by Blue Heron Biotechnology (Bothell, WA). Plasmid C-wt contains the
wild-type HIV-1 subtype C partial pol gene between nucleotides 2294 and
3283, according to the HIV strain HXB2 reference sequence (34). Plasmid
C-mut1 carries the DRMs V32I, I47V, L76V, I84V, and L90M in the pro-
tease region, and M41L, K65R, K70R, L74V, L100I, K101P, K103N,
V106A, Y115F, Q151M, Y181C, M184V, Y188L, G190A, and K219Q in
the reverse transcriptase (RT) region. Plasmid C-mut2 carries the DRM
I47A in the protease region and K101E, K103R, V106M, and K219E in the
RT region. These three plasmids were used in the initial assay develop-
ment, optimization, and sensitivity determination.
Development of the multiplex allele-specific HIVDR assay for
HIV-1 subtype C. To test the validity of each of the ASPE primers, we
amplified the plasmid DNAs individually by PCR. One microliter of 10
ng/l plasmid DNAs (equivalent to 1,618 viral DNA copies) was added to
100 l of the PCR mixture, containing 0.2 M primers M13F (5=-CCCAG
TCACG ACGTT GTAAA ACG-3=) and M13R (5=-AGCGG ATAAC
AATTT CACAC AGG-3=), 1 High Fidelity PCR buffer, 2.0 mM MgSO4,
and 2.0 U of Platinum Taq High Fidelity (Life Technologies, Bethesda,
MD). PCR was conducted as follows: 2 min at 94°C, 30 cycles of 20 s at
94°C, 20 s at 55°C, and 90 s at 68°C, and 5 min at 68°C. The PCR products
were purified using the ExoSAP-IT PCR cleanup kit (USB Co., Cleveland,
OH). The purified PCR products of plasmids C-wt and C-mut1, a mixture
of the two at a 1:1 ratio (wt/wt), and a no-target PCR negative control
(NC) were used to validate each of the WT and Mut ASPE primers. A
multiplex ASPE assay was optimized for several factors affecting the spec-
ificity and signal output. These included Mg2 concentration, polymerase
concentration, cycling parameters, annealing temperature, ASPE primer
length, ASPE primer concentrations, and the amount of PCR product
used in the ASPE reaction mixture. Once the specificities of the individual
primers were confirmed and the assay conditions were optimal, we com-
bined all 45 ASPE primers and performed the multiplex ASPE (mASPE)
assay in a single tube using Tsp DNA polymerase (Invitrogen, Carlsbad,
CA) and reaction buffer that allows for a relatively wide range of annealing
temperatures. Briefly, for each 20-l mASPE reaction mixture, it con-
tained 5 l purified PCR product, 1.5 U Tsp DNA polymerase, 9.5  1011
copies of each ASPE primer (Table 1), 10.0 M (each) dATP, dTTP,
dGTP, and biotin-dCTP (Invitrogen, Carlsbad, CA), 20.0 mM Tris-HCl
(pH 8.4), 50.0 mM KCl, and 1.88 mM MgCl2. The reaction mixtures were
subjected to the following PCR conditions: initial denaturation at 96°C for
2 min followed by 30 cycles of 94°C for 30 s, 55°C for 1 min, and 74°C for
2 min. Next, 10 l of mASPE products was added to a 40-l microsphere
hybridization mixture containing 2.2  103 of each microsphere set and
2 Tm hybridization buffer (0.2 M Tris-HCl [pH 8.0], 0.4 M NaCl, 0.16%
Triton X-100). The ASPE-bead mixtures were subjected to denaturation
at 96°C for 90 s and annealing at 37°C for 30 min, and the reaction mix-
tures were placed on a magnetic separator for 60 s. After discarding the
supernatant, the microspheres were resuspended in 100 l 1 Tm hy-
bridization buffer containing 4 g/ml streptavidin R-phycoerythrin (Mo-
lecular Probes, Eugene, OR) and incubated at 37°C for 15 min. Finally, the
100-l reaction mixture was analyzed with the Bio-Plex 3D suspension
array system to determine the median fluorescence intensity (MFI) value
for at least 100 microspheres for each of the 45 sets of microspheres. The
MFI value for each bead set was corrected by subtracting the value of the
no-target PCR negative control, and the resulting net MFI values were
used for the calculation of the allelic ratio (AR). The AR is equal to the net
MFI for an allele divided by the sum of the net MFIs for all alleles tested for
a given mutation site, which represents the fraction of the total net MFI
signal for the mutation site attributed to the presence of a particular allele.
Threshold values were determined according to procedures described in
previous studies (35, 36); an AR of 0.10 indicated the presence of a
particular allele, and if more than one allele had an AR of 0.10, a mixture
was called. Figure 1 is a schematic illustration of the mASPE and suspen-
sion array analysis processes.
Determination of the assay sensitivity. To determine the sensitivity
of the MAS assay for each of the Mut alleles, we diluted the two Mut
plasmid DNAs with the WT plasmid DNA. Ten nanograms per microliter
of C-mut1 or C-mut2 plasmid DNA was mixed with the WT plasmid
DNA, resulting in 2-fold serial dilutions with Mut template at levels of
100%, 50%, 25%, 12.5%, 6.25%, 3.12%, 1.56%, and 0%. One microliter of
each serial dilution was used for PCR amplification, and each of the 5-l
amplicons was used to perform a multiplex ASPE assay with all 45 ASPE
primers in a single tube reaction, and 10 l of the mASPE products was
analyzed following the procedure described above. The sensitivity of the assay
for each allele was determined based on the results from three independent
experiments. The lowest concentration at which all three replicates were pos-
itive was defined as the sensitivity of the assay for a given allele.
Application of the MAS assay with clinical specimens. Plasma speci-
mens collected from 148 individuals infected with HIV-1 subtype C from
Zambia and Malawi (37, 38) with known viral loads (VLs) ranging from 2.43
to 6.50 log10 copies/ml were analyzed. They were collected from 71 ART-
experienced patients and 77 ART-naive patients who were eligible for ART at
the time of specimen collection. All the specimens were collected under insti-
tutional review board-approved protocols. The tests conducted for the MAS
assay using deidentified specimens were determined to be non-human sub-
ject research by the associate director for Science at the Center for Global
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TABLE 1 ASPE primers for HIV-1 group M subtype C
Primer no. Typea Sequence (5= to 3=) Tag IDb Positionc
1 M41 Tag-AAG ARA AAA TAA AAG CAT TAA YAG MAA TTT GTG AWG ARA 45 2632¡2670
2 41L Tag-AAG ARA AAA TAA AAG CAT TAA YAG MAA TTT GTG AWG ARC 38 2632¡2670
3 K65 Tag-AAA TCC ATA TAA CAC TCC ART ATT TGC YAT AAA RAA 12 2708¡2743
4 65R Tag-AAA TCC ATA TAA CAC TCC ART ATT TGC YAT AAA RAG 13 2708¡2743
5 K70 Tag-CCA GTA TTT GCC ATA AAG ARG AAR GAY AGT ACT AA 18 2724¡2758
6 70R Tag-CCA GTA TTT GCC ATA AAG ARG AAR GAY AGT ACT AG 21 2724¡2758
7 L74 Tag-CAT AAA AAA GAA RGA CAG TAC HAR RTG GAG AAA AT 67 2735¡2769
8 74V Tag-CAT AAA AAA GAA RGA CAG TAC HAR RTG GAG AAA AG 90 2735¡2769
9 Y115 Tag-AGT RCT RGA YGT GGG RGA TGC ATA 73 2870¡2893
10 115F Tag-AGT RCT RGA YGT GGG RGA TGC ATT 62 2870¡2893
11 Q151 Tag-GGA TTA GRT ATC AAT ATA ATG TRY TNC CAC 29 2971¡3000
12 151M Tag-GGA TTA GRT ATC AAT ATA ATG TRY TNC CAA 36 2971¡3000
13 M184 Tag-AGR GCA AAA AAT CCA GAM RTR GTY ATC TRY CAA TAY A 37 3063¡3099
14 184V Tag-AGR GCA AAA AAT CCA GAM RTR GTY ATC TRY CAA TAY G 22 3063¡3099
15 K219 Tag-AAR TGG GGR TTT ACY ACA CCA GAC A 53 3180¡3204
16 219Q Tag-AAR TGG GGR TTT ACY ACA CCA GAC C 44 3180¡3204
17 219E Tag-AAR TGG GGR TTT ACY ACA CCA GAK G 96 3180¡3204
18 L100 Tag-CAA TTA GGR ATA CCA CAC CCA KCA GGR T 42 2820¡2847
19 100I Tag-CAA TTA GGR ATA CCA CAC CCA KCA GGR A 58 2820¡2847
20 K101 Tag-AAT TAG GRA TAC CAC ACC CAK CAG GRW TRA 55 2821¡2850
21 101P Tag-AAT TAG GRA TAC CAC ACC CAK CAG GRW TRC C 89 2821¡2851
22 101E Tag-AAT TAG GRA TAC CAC ACC CAK CAG GRW TRG 65 2821¡2850
23 K103 Tag-GAA TAC CAC ACC CAK CAG GGT TRA ARA AGA AA 19 2827¡2858
24 103N Tag-GAA TAC CAC ACC CAK CAG GGT TRA ARA AGA AY 66 2827¡2858
25 103R Tag-GAA TAC CAC ACC CAK CAG GGT TRA ARA AGA GA 63 2827¡2858
26 V106 Tag-ACA CCC AKC AGG GTT AAA RAA GAA HAA RTC WGT 20 2834¡2866
27 106A Tag-ACA CCC AKC AGG GTT AAA RAA GAA HAA RTC WGC 39 2834¡2866
28 106M Tag-CAC ACC CAK CAG GGT TAA ARA AGA AHA ART CWA 75 2833¡2865
29 Y181 Tag-GCC CTT TAG RRC AMA AAA TCC AGA MVT RGT YAT CTA 9 3056¡3091
30 181C Tag-GCC CTT TAG RRC AMA AAA TCC AGA MVT RGT YAT CTG 82 3056¡3091
31 Y188 Tag-CAG AAA TRG TYA TCT RTC AAT AYR TRG ATG AYT TRT A 83 3076¡3112
32 188L Tag-CAG AAA TRG TYA TCT RTC AAT AYR TRG ATG AYT TRC T 93 3076¡3112
33 G190 Tag-ATA GTY ATC TRT CAA TAT RTG GAT GAC TTR TAT GTR GG 97 3081¡3118
34 190A Tag-ATA GTY ATC TRT CAA TAT RTG GAT GAC TTR TAT GTR GC 76 3081¡3118
35 V32 Tag-CTC TYT TAG AYA CAG GAG CAG ATG AYA CAG 14 2317¡2346
36 32I Tag-CTC TYT TAG AYA CAG GAG CAG ATG AYA CAA 48 2317¡2346
37 I47 Tag-TGC CAG GRA RAT GGA AAC CAA RAA TRA 30 2365¡2391
38 47V Tag-GCC AGG RAR ATG GAA ACC AAR AAT RGT 43 2366¡2392
39 47A Tag-GCC AGG RAR ATG GAA ACC AAR AAT RGC 78 2366¡2392
(Continued on following page)
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Health at CDC. The nested PCR products obtained previously by a broadly
sensitive genotyping assay (13, 14) were analyzed using the MAS assay.
Verification of low-abundance alleles detected by the MAS assay. To
verify the additional low-abundance alleles detected by the MAS assay, 16 of
the 24 specimens with low-abundance alleles were amplified using primers
tagged with multiplex identifiers (39) and then were pooled and pyrose-
quenced using the Roche 454 GS-FLX Titanium sequencing kit XLR70
(Roche Applied Science, Indianapolis, IN, USA) following the manufactur-
er’s protocol. Six overlapping primer sets (three each forward and reverse)
were used for bidirectional coverage of the protease (amino acids 6 to 99) and
RT (amino acids 1 to 251) regions (Z. Zhou, K. Tang, G. Zhang, N. Wadonda-
Kabondo, L. A. Rowe, J. R. DeVos, N. Wagar, J. Nkengasong, M. Frace, S.
Sammons, and C. Yang, unpublished data).
Statistical analysis. The means, standard deviations (SD), and coeffi-
cients of variation (CVs) were calculated for net MFI in the repeat runs of
plasmid DNA templates. The agreement between the MAS and in-house se-
quencing-based assays was assessed by calculating concordance with the 95%
confidence interval (CI). The chi-square test was applied for a comparison of
the categorical data. Statistical calculations were performed with the SPSS
20.0 (SPSS, Inc., Chicago, IL) and Microsoft Excel 2010 (Microsoft Corp.,
Redmond, WA, USA) software packages.
Nucleotide sequence accession numbers. The nucleotide sequences
of the three plasmids C-wt, C-mut1, and C-mut2 were submitted to
GenBank under accession no. KF019640 to KF019642.
RESULTS
Development of the MAS assay using specially constructed plas-
mid DNAs. For the initial development of the MAS assay, two
plasmids (C-wt and C-mut1) and a mixture of them at a 1:1 ratio
TABLE 1 Continued
Primer no. Typea Sequence (5= to 3=) Tag IDb Positionc
40 L76 Tag-AAA TTT GTG GRA AAA ARG CTR TAG GTA CAG TRT 28 2446¡2478
41 76V Tag-AAA TTT GTG GRA AAA ARG CTR TAG GTA CAG TRG 70 2446¡2478
42 I84 Tag-AGT ATT ART RGG RCC TAC ACC TGT CAA YA 35 2474¡2502
43 84V Tag-AGT ATT ART RGG RCC TAC ACC TGT CAA YG 77 2474¡2502
44 L90 Tag-CCT ACA CCT GTC AAC ATA ATT GGR AGR AAY HTR T 95 2487¡2520
45 90 M Tag-CCT ACA CCT GTC AAC ATA ATT GGR AGR AAY HTR A 57 2487¡2520
a One primer was designed for each wild-type and mutant allele at 20 drug resistance mutation loci, and five loci have two types of mutant allele, so a total of 45 ASPE primers were
designed.
b Each Tag matches with one of the MagPlex-TAG microspheres (Luminex Corp., Austin, TX, USA). ID, identification.
c Positions based on HXB2 sequence positions from 5= to 3=.
FIG 1 Schematic illustration of the MAS assay. The MAS assay starts with an allele-specific primer extension (ASPE) with all allele-specific primers mixed
together in one reaction tube containing the reaction reagent mixture and a template. For the primer with a matching 3=-terminal nucleotide, primer extension
occurs and biotinylated dCTPs are incorporated into the extended product. During the hybridization step, ASPE products are uniquely annealed to microspheres
through the specificity of Tag/anti-Tag recognition. Finally, the hybridization products are read with the suspension array system, which identifies each
microsphere set by its internal dye and records the associated reporter dye intensity as the mean fluorescence intensity (MFI).
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(wt/wt) were analyzed. Figure 2 shows the results of the two plas-
mid templates (C-wt and C-mut1) for all 20 codons from five
independent test runs after testing conditions had been opti-
mized. The mean background MFI for each allele ranged from
12.56 to 127.94. The mean  SD of the highest background value
was 127.94  19.41, and the 99% upper confidence limit, which
corresponded to the mean plus 2.58 SD, was 178.02. Based on this
calculation, the minimal valid allele-calling MFI value was set at
180. If these criteria were met, the allele was determined using
the AR. With these criteria, each of the WT and Mut alleles in the
plasmid templates was correctly detected. As shown in Fig. 2, the
assay had good reproducibility, as evidenced by the low SD be-
tween testing runs. The CVs for the positive signals of each WT
allele were 2.43% to 15.42%, and the CVs for the positive signals of
each Mut allele were 3.41% to 11.68%.
Sensitivity of the MAS assay. The results from three indepen-
dent testing runs of serial dilutions of Mut templates (C-mut1 and
C-mut2) are shown in Fig. 3. Although the MFI values varied
between different Mut alleles, a significant concentration-depen-
dent relationship was observed for each Mut allele. At a cutoff
value of 180 and a AR of 0.1, the MAS assay detected 1.56% of
the minority mutant populations of K219Q and K219E, 3.13% of
L76V, 6.25% of K65R, K70R, L74V, L100I, K103N, K103R,
Q151M, Y181C, and I47V, and 12.5% of M41L, K101P, K101E,
V106A, V106M, Y115F, M184V, Y188L, G190A, V32I, I47A, I84V,
and L90M.
Analysis of plasma specimens from ART-experienced and
ART-naive patients. The purified nested PCR products from 148
patient specimens were analyzed using the MAS assay. In all, 2,960
codons (20 codons per specimen, 148 specimens) were analyzed,
of which 2,887 (97.53% [95% CI, 96.91 to 98.06]) were genotyped;
the remaining 73 codons had indeterminate results due to nega-
tive reactions for both the WT and Mut alleles. The mean MFI for
the positive signals in patient specimens was 2,823 (95 percentile
interval, 525.0 to 6,720.2), and the mean MFI for negative signals
in patient specimens was 59.80 (95 percentile interval, 8.48 to
FIG 2 Detection of drug resistance mutations using plasmid DNA templates. After PCR amplification of each template individually, a mixture of the wild-type
template and the mutant template (Mut) at a ratio of 1:1 (wt/wt), amplicons of each individual template, and a no-target negative control (NC) were analyzed
with the 45 ASPE primers. The data shown are means plus standard deviations (SD) (error bars) (n  5).
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140.0), which are comparable to those obtained from plasmid
templates. Analyses of the DRMs at 20 loci showed that eight mu-
tation sites had identical genotyping results, while the remaining
12 sites were 95.21% to 99.32% concordant between the MAS
assay and conventional sequencing (Table 2).
Overall, among the 2,887 codons detected by both MAS and
sequencing-base assays, 2,855 (98.89% [95% CI, 98.44 to
99.21]) were identical and 32 were discordant between the two
assays. The concordance rates between the two methods in
ART-experienced and ART-naive patients were 98.54% (1,353/
1,373) (95% CI, 97.76% to 99.05%) and 99.21% (1,502/1,514)
(95% CI, 98.62% to 99.55%), respectively, which were not sig-
nificantly different between the two groups of patients (2 
2.90, P  0.09). In total, there were 32 discordant allele calls,
and among them, 24 were identified as mixtures by the MAS
assay, while they were identified as nonmixtures by sequenc-
ing-based assay (15 WTs and 9 Muts). To the contrary, seven
codons identified as mixtures by the sequencing-based assay
were interpreted as WTs (n  5) and Muts (n  2) by the MAS
assay, and the one remaining specimen, MW4644 from Ma-
lawi, was a Mut at 181C using the sequencing assay and was a
wild-type Y181 using the MAS assay. Sequencing results
showed that the MAS assay missed these alleles due to mis-
matches between the ASPE primers and viral sequences.
Of the 73 indeterminate results from the MAS assay, sequenc-
ing results indicated that 58 were WTs, seven were Muts, two were
a mixture of WTs and Muts, and the remaining six were untar-
geted alleles, including one K101Q, Y181I, Y188H, and G190S,
and two Y188Cs. These indeterminate results were caused by the
failure of the ASPE primers to either hybridize or extend during
primer extension. Analysis of the sequences generated by conven-
tional sequencing revealed three reasons for the indeterminate
results: (i) an unexpected mutation within close proximity to the
polymorphism site (at the 3= end of ASPE primer), (ii) multiple
mutations within the span of the ASPE primers, or (iii) an untar-
geted Mut allele that was not included in the assay.
Results of 454 ultradeep pyrosequencing. Sixteen of the 24
low-abundance alleles detected using the MAS assay were further
analyzed by Roche 454 ultradeep sequencing. All but one low-
abundance allele (K65R in MW5549 collected from Malawi) were
verified by ultradeep sequencing. The ultradeep sequencing
tagged with multiplex identifiers yielded an average of 2,258 reads
per base, with a range of 332 to 5,591 reads per base, and the results
showed that the proportions of low-abundance Mut alleles missed
FIG 3 Sensitivity for detection of drug resistance mutations at 20 mutation sites. Twofold serial dilutions of the Mut template against the WT template were
tested with the MAS assay. The data shown are the means plus SD (error bars) (n  3).
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by Sanger sequencing were 3.61% to 27.29%. Since several steps of
amplification were involved prior to pyrosequencing, the accu-
racy of these proportions is unverifiable. Nevertheless, the ul-
tradeep sequencing results confirmed the higher sensitivity of the
MAS assay than that of conventional sequencing in detecting
low-abundance alleles.
DISCUSSION
We describe the development and validation of a multiplex allele-
specific HIV-1 subtype C DR detection assay using suspension
array technology that can simultaneously detect a set of genetic
mutations associated with the resistance of HIV-1 to the com-
monly used NNRTIs, NRTIs, and PIs. This novel assay can simul-
taneously detect 45 alleles in a single reaction tube and has good
concordance with a well-validated in-house sequencing-based
method (13). Specimens from both ART-experienced and ART-
naive patients were analyzed successfully by the MAS assay, indi-
cating the potential utility of this assay to detect both acquired and
transmitted DRMs.
The results of 2-fold serial dilutions of the Mut templates in a
WT background demonstrated that the MAS assay reliably de-
tected Mut alleles at low levels of 1.56% to 12.5%, while direct
sequence analysis has less sensitivity for polymorphism detection,
approximately 15 to 20% (40). More low-abundance alleles in
patient specimens were detected by the MAS assay as verified by
454 ultradeep sequencing, further confirming the increased sen-
sitivity of the MAS assay. This increased sensitivity will reduce the
chance of missing low-abundance DRMs, which may have clinical
significance for treatment outcomes (17, 41). However, like any
allele-specific DR detection assay, the higher sensitivity for detect-
ing low-abundance variants is input copy number dependent;
thus, low-abundance variants may still be missed when the patient
specimens used for the analysis have low viral load levels.
Traditional sequencing-based DR assays require six to eight se-
quencing reaction tubes/wells per sample to cover the minimal re-
gions for which sequence data need to be collected in the pol region.
This increases the time spent to complete testing for each sample and
the analysis time for generating a consensus sequence from the 6 to 8
contigs to a week or more. The use of the 45-plex suspension array
assay reduces the number of tubes/wells used for each sample testing
to one, and the time to results is substantially reduced. After initial
reverse transcription-PCR (RT-PCR) and nested PCR amplification
and purification, it takes 8 h to perform the entire procedure, in-
cluding the mASPE reaction (4.0 h), hybridization to microspheres
(1.0 h), incubation with reporter dye (0.5 h), instrument readout (1.0
h), and data analysis (0.5 h). As only one tube/reaction well is re-
quired per sample, this allows for the genotyping of 96 or 384 samples
(including controls) to occur in one plate, which can be accomplished
within one work day. Therefore, this method is especially suitable for
large-scale ongoing surveillance of HIVDR.
The high-throughput nature of the MAS assay substantially
reduces its cost. To estimate the reagent cost, we included the cost
associated with RNA extraction, primer synthesis, RT-PCR and
nested PCR amplification, PCR purification, mASPE, hybridiza-
tion, and suspension array detection. We calculated a cost of
$40.90 (U.S. market price) per sample for the MAS assay, which is
comparable to the inexpensive in-house sequencing assay ($40.00
per sample) and considerably lower than that for commercially
available genotyping assays, such as ViroSeq ($213.20 per sample)
and TruGene ($172.86 per sample) (14). Moreover, the instru-
mentation for the MAS assay is more affordable. The latest com-
pact suspension array system, Magpix (Luminex Corp., Austin,
TX), costs only one-tenth that of an ABI 3730 sequencer (Applied
Biosystems, Foster City, CA).
Another advantage of the MAS assay over sequencing is that
this assay is simpler to perform and the resulting data are easier to
interpret. Once an assay run is completed, the genotyping results
are immediately available and the data can be reported.
Due to the flexibility of the suspension array technology,
which currently permits multiplexed analysis of up to 500 in-
dividual analytes per tube or well, additional mutations of bi-
ological significance can be easily incorporated into the current
assay. As such, the MAS assay can be readily adapted for differ-
ent surveillance purposes, as well as for clinical use, by adding
or removing ASPE primers and the corresponding micro-
spheres to the assay.
As with any DR genotyping assays, the MAS assay has its
limitations. First, it can only be used to analyze known DR
mutations and it does not provide sequence data. This issue is
common to any other point mutation assays, such as the AS-
PCR, OLA, and PASS. Second, due to significant genetic vari-
ation between different HIV-1 subtypes, ASPE primers de-
signed based on one subtype sequence may not work well for
other subtypes. Currently, we are modifying the primers and
validating the assay for HIV-1 non-C subtypes. Third, the assay
TABLE 2 Concordance between population sequencing and the MAS
assay in DR mutation genotyping of patient specimens (n  148) at















rt 41 145 (97.97) 144 (99.31) 1 0
65 148 (100.0) 145 (97.97) 3 3
70 142 (95.95) 141 (99.30) 1 1
74 144 (97.30) 144 (100.0) 0 0
115 145 (97.97) 145 (100.0) 0 0
151 143 (96.62) 143 (100.0) 0 0
184 137 (92.57) 134 (97.81) 3 2
219 142 (95.95) 141 (99.30) 1 0
100 143 (96.62) 143 (100.0) 0 0
101c 147 (99.32) 143 (97.28) 4 2
103 146 (98.65) 139 (95.21) 7 5
106 148 (100.0) 146 (98.65) 2 2
181c 137 (92.57) 135 (98.54) 2 1
188c 143 (96.62) 141 (98.60) 2 2
190c 145 (97.97) 140 (96.55) 5 5
prt 32 148 (100.0) 148 (100.0) 0 0
47 148 (100.0) 148 (100.0) 0 0
76 140 (94.59) 140 (100.0) 0 0
84 148 (100.0) 148 (100.0) 0 0
90 148 (100.0) 147 (99.32) 1 1
Total 2,887 (97.53) 2,855 (98.89) 32 24
a The concordance rate equals the number of concordant specimens divided by the
number of alleles detected.
b Number of additional mixtures detected by the MAS assay.
c Six untargeted alleles at four loci could not be detected because no ASPE primers were
designed for them; these include one K101Q, Y181I, Y188H, G190S, and two Y188C.
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is a qualitative assay and cannot be used for the quantification
of DR mutations.
In conclusion, we have developed and validated a multiplex
allele-specific subtype C DR detection assay. This assay not only
saves time and resources for high-throughput detection of DR
mutations but also has the flexibility to add or delete DR muta-
tions based on specific needs. Therefore, the MAS assay may rep-
resent an efficient and flexible approach for the surveillance and
monitoring of HIVDR in countries where subtype C viruses pre-
dominate.
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